To see the other types of publications on this topic, follow the link: Roflumilast.

Journal articles on the topic 'Roflumilast'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Roflumilast.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Yosipovitch, Gil, Shawn Kwatra, James Del Rosso, et al. "Reduction in Pruritus Across Indications in Phase 3 Trials of Topical Roflumilast." SKIN The Journal of Cutaneous Medicine 9, no. 4 (2025): s587. https://doi.org/10.25251/579nct27.

Full text
Abstract:
Background: Pruritus is a burdensome symptom affecting quality of life (QOL) in patients with seborrheic dermatitis (SD), psoriasis, and atopic dermatitis (AD). Phosphodiesterase4 (PDE4) inhibitors may reduce pruritus by reducing inflammatory itch mediators. Topical roflumilast, formulated as a water-based foam or cream without penetration enhancers or fragrances, is a selective, highly potent PDE4 inhibitor. Efficacy and safety of once-daily, topical roflumilast has been demonstrated in patients with psoriasis (cream 0.3% and foam 0.3%), SD (foam 0.3%), and AD (0.15% and 0.05% cream). Methods
APA, Harvard, Vancouver, ISO, and other styles
2

Livingston, Nicholas R., Peter CT Hawkins, James Gilleen, et al. "Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia." Journal of Psychopharmacology 35, no. 9 (2021): 1099–110. http://dx.doi.org/10.1177/02698811211000778.

Full text
Abstract:
Background: Cognitive flexibility deficits are present in patients with schizophrenia and are strong predictors of functional outcome but, as yet, have no pharmacological treatments. Aims: The purpose of this study was to investigate whether the phosphodiesterase type-4 inhibitor, roflumilast, can improve cognitive flexibility performance and functional brain activity in patients with schizophrenia. Methods: This was a within-subject, randomised, double-blind, placebo-controlled, three-period crossover study using a version of the Intradimensional/Extradimensional (ID/ED) task, optimised for f
APA, Harvard, Vancouver, ISO, and other styles
3

Alispahic, Imane Achir, Rikke Sørensen, Josefin Eklöf, et al. "Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations." Journal of Clinical Medicine 9, no. 5 (2020): 1442. http://dx.doi.org/10.3390/jcm9051442.

Full text
Abstract:
Roflumilast is given as an add-on to inhalation medication in patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis. Animal experiments have documented deleterious effects of roflumilast in bacterial infections, but trials have not reported the risk of bacterial infections in patients. The objective of this study is to determine, among outpatients with severe COPD in a two-year follow-up period, the risk of hospitalization-requiring pneumonia, severe acute exacerbation in COPD (AECOPD-hosp), and death. Patients with COPD using roflumilast (roflumilast users) were co
APA, Harvard, Vancouver, ISO, and other styles
4

Nicolas, Samar E., Michael D. Bear, Abir O. Kanaan, Oana Andreia Coman, and Lorena Dima. "Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis." American Journal of Therapeutics 30, no. 6 (2023): e535-e542. http://dx.doi.org/10.1097/mjt.0000000000001678.

Full text
Abstract:
Background: Plaque psoriasis is a chronic dermatologic autoimmune disease that affects adults and children. Roflumilast 0.3% cream is currently the only topical phosphodiesterase 4 inhibitor indicated for the treatment of plaque psoriasis in patients 12 years or older. Pharmacodynamics and Pharmacokinetics: Roflumilast inhibits phosphodiesterase 4 inhibitor enzyme leading to the accumulation of cyclic adenosine monophosphate, which suppresses the inflammatory mediators interferon-γ and tumor necrosis factor-α. Roflumilast, applied once daily, reaches steady state by day 15 and has a half life
APA, Harvard, Vancouver, ISO, and other styles
5

&NA;. "Roflumilast." Drugs in R & D 5, no. 3 (2004): 176–81. http://dx.doi.org/10.2165/00126839-200405030-00009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sanford, Mark. "Roflumilast." Drugs 70, no. 12 (2010): 1615–27. http://dx.doi.org/10.2165/11205930-000000000-00000.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Christie, P. "Roflumilast." Drugs of Today 41, no. 10 (2005): 667. http://dx.doi.org/10.1358/dot.2005.41.10.920428.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cada, Dennis J., Terri L. Levien, and Danial E. Baker. "Roflumilast." Hospital Pharmacy 46, no. 8 (2011): 597–606. http://dx.doi.org/10.1310/hpj4608-597.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fabbri, Leonardo M., Bianca Beghé, Uma Yasothan, and Peter Kirkpatrick. "Roflumilast." Nature Reviews Drug Discovery 9, no. 10 (2010): 761–62. http://dx.doi.org/10.1038/nrd3276.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sorbera, L. A., P. A. Leeson, and J. Castañer. "Roflumilast." Drugs of the Future 25, no. 12 (2000): 1261. http://dx.doi.org/10.1358/dof.2000.025.12.604045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Cao, Hong-Ying, Tian-Hua Yu, Cui-Hong Han, Wen-Wu Liu, Pei-Xi Zhang, and Peng Tang. "Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation." Undersea and Hyperbaric Medicine 47, no. 2 (2020): 189–96. http://dx.doi.org/10.22462/04.06.2020.3.

Full text
Abstract:
Roflumilast is an inhibitor of phosphodiesterase-4 (PDE4) and can suppress the hydrolysis of cAMP in inflammatory cells, conferring anti-inflammatory effects. This study aimed to investigate the protective effects of roflumilast on hyperoxia-induced acute lung injury (HALI) in a rat model. Male Sprague-Dawley rats were randomly assigned into: control group; HALI group; 2.5 mg/kg roflumilast group; and 5 mg/kg roflumilast group. Rats were pressurized to 250 kPa with pure oxygen to induce lung injury. In the roflumilast groups, rats were orally administered with roflumilast at 2.5 or 5 mg/kg onc
APA, Harvard, Vancouver, ISO, and other styles
12

Rehman, Najeeb Ur, Mohd Nazam Ansari, and Abdul Samad. "In Silico, Ex Vivo and In Vivo Studies of Roflumilast as a Potential Antidiarrheal and Antispasmodic agent: Inhibition of the PDE-4 Enzyme and Voltage-gated Ca++ ion Channels." Molecules 25, no. 4 (2020): 1008. http://dx.doi.org/10.3390/molecules25041008.

Full text
Abstract:
The aim of the present study was to evaluate the possible gut inhibitory role of the phosphodiesterase (PDE) inhibitor roflumilast. Increasing doses of roflumilast were tested against castor oil-induced diarrhea in mice, whereas the pharmacodynamics of the same effect was determined in isolated rabbit jejunum tissues. For in silico analysis, the identified PDE protein was docked with roflumilast and papaverine using the Autodock vina program from the PyRx virtual screening tool. Roflumilast protected against diarrhea significantly at 0.5 and 1.5 mg/kg doses, with 40% and 80% protection. Ex viv
APA, Harvard, Vancouver, ISO, and other styles
13

Maiga, Mariama C., Bintou Ahmadou Ahidjo, Mamoudou Maiga, and William R. Bishai. "Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis." Antimicrobial Agents and Chemotherapy 59, no. 12 (2015): 7888–90. http://dx.doi.org/10.1128/aac.02145-15.

Full text
Abstract:
ABSTRACTWith phosphodiesterase inhibitors (PDE-Is) showing significant promise in shortening tuberculosis treatment, we assessed the effect of roflumilast, an FDA-approved type 4 PDE-I, in both acute and chronic murine models of tuberculosis. Alone, roflumilast had no effect on lung bacillary burden and mortality. However, when roflumilast was used in combination with isoniazid, a reduction in lung bacillary burden was observed. These data suggest that roflumilast may be a good candidate for tuberculosis host-directed therapy (HDT).
APA, Harvard, Vancouver, ISO, and other styles
14

Octafia, Ita, Dwi Octamy Sari, Novi Wulandari, et al. "Roflumilast: A Review of Chronic Obstructive Pulmonary Disease (COPD) Treatment." Qanun Medika - Medical Journal Faculty of Medicine Muhammadiyah Surabaya 5, no. 1 (2021): 35. http://dx.doi.org/10.30651/jqm.v5i1.5043.

Full text
Abstract:
Abstract Chronic Obstructive Pulmonary Disease (COPD) is a chronic airway inflammation with resulting progressive airflow limitation that has a high incidence, morbidity, and mortality. Roflumilast is an oral phosphodiesterase-4 inhibitor as a therapy to decrease the risk of COPD exacerbations in patients with moderate-severe COPD with a history of chronic bronchitis. Roflumilast can be given orally once daily as a single or combination drug. It can be used as COPD moderate-severe but also more beneficial as COPD mild treatment. The efficacy of Roflumilast can prevent exacerbations of repetiti
APA, Harvard, Vancouver, ISO, and other styles
15

Murad, Hussam A., Hamed S. Habib, Misbahuddin M. Rafeeq, Mansour I. Sulaiman, Amer S. Abdulrahman, and Mohamad Nidal Khabaz. "Co-inhalation of roflumilast, rather than formoterol, with fluticasone more effectively improves asthma in asthmatic mice." Experimental Biology and Medicine 242, no. 5 (2017): 516–26. http://dx.doi.org/10.1177/1535370216685006.

Full text
Abstract:
Roflumilast is approved as an add-on therapy for chronic obstructive pulmonary disease. The inflammation in chronic obstructive pulmonary disease is mainly neutrophilic, while in asthma it is mainly eosinophilic, studies addressing role of roflumilast in eosinophilic inflammation are recommended. Also in severe asthma, the dominant inflammatory cells are neutrophils. Thus, roflumilast has a potential off-label use in the treatment of asthma. This study was designed to evaluate the effects of co-inhalation of roflumilast and fluticasone compared to that of formoterol and fluticasone in ovalbumi
APA, Harvard, Vancouver, ISO, and other styles
16

Peng, Sheng, Hong-Zhu Yan, Pei-Rong Liu, et al. "Phosphodiesterase 4 Inhibitor Roflumilast Protects Rat Hippocampal Neurons from Sevoflurane Induced Injury via Modulation of MEK/ERK Signaling Pathway." Cellular Physiology and Biochemistry 45, no. 6 (2018): 2329–37. http://dx.doi.org/10.1159/000488180.

Full text
Abstract:
Background/Aims: Sevoflurane, a commonly used volatile anesthetic, recently has been found has neurotoxicity in the central nervous system of neonatal rodents. This study aimed to reveal whether phosphodiesterase 4 (PDE-4) inhibitor roflumilast has protective functions in sevoflurane-induced nerve damage. Methods: Hippocampal neurons were isolated from juvenile rats, and were exposed to sevoflurane with or without roflumilast treatment. Cell viability and apoptosis were respectively assessed by CCK-8 and flow cytometry. Western blot analysis was performed to detect the protein expressions of a
APA, Harvard, Vancouver, ISO, and other styles
17

Wang, Hao, Fang-fang Zhang, Yong Xu, et al. "The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice." International Journal of Neuropsychopharmacology 23, no. 10 (2020): 700–711. http://dx.doi.org/10.1093/ijnp/pyaa048.

Full text
Abstract:
Abstract Background Depression is highly related to Alzheimer’s disease (AD), yet no effective treatment is available. Phosphodiesterase-4 (PDE4) has been considered a promising target for treatment of AD and depression. Roflumilast, the first PDE4 inhibitor approved for clinical use, improves cognition at doses that do not cause side effects such as emesis. Methods Here we examined the effects of roflumilast on behavioral dysfunction and the related mechanisms in APPswe/PS1dE9 transgenic mice, a widely used model of AD. Mice at 10 months of age were examined for memory in the novel object rec
APA, Harvard, Vancouver, ISO, and other styles
18

Smythe, Ciaran, Alice Sohn, Eingun James Song, and George Michael Lewitt. "Successful Treatment of Seborrheic Dermatitis with Topical Roflumilast: A Case Series." SKIN The Journal of Cutaneous Medicine 8, no. 5 (2024): 1889–92. http://dx.doi.org/10.25251/skin.8.5.20.

Full text
Abstract:
Background: Seborrheic dermatitis (SD) is a common skin disease that presents with pink scaly patches in areas with higher sebaceous gland density, such as the scalp, glabella, retroauricular folds, nasolabial folds, chest, and groin. Case Reports: This is a case series of two patients with longstanding SD that did not respond adequately to topical corticosteroids or azoles, and were successfully treated monotherapy with roflumilast cream 0.3%. Both patients responded within two months and continue to respond to treatment with topical roflumilast monotherapy. Discussion: SD is commonly conside
APA, Harvard, Vancouver, ISO, and other styles
19

Pamila, Miss, Ramya Sugumar, and Darling Chellathai David. "Evaluation of Roflumilast (BCRP inhibitor) and Methotrexate (BCRP substrate) on Viability of Primary Squamous Cell Carcinoma – An in vitro Study." Biomedical and Pharmacology Journal 12, no. 2 (2019): 683–87. http://dx.doi.org/10.13005/bpj/1689.

Full text
Abstract:
In this study we evaluated the possible beneficial drug- interaction between Roflumilast (BCRP inhibitor) and Methotrexate (BCRP substrate) on viability of primary squamous cell carcinoma cell line using an in vitro technique. The KB cell line was treated with Roflumilast and Methotrexate to evaluate its anticancer activity using MTT assay. Image analysis under phase contrast microscopy was performed and flow-cytometry was done to see for cell cycle arrest as a result of drug treatment. Cell viability gradually decreased with the increasing concentrations of roflumilast, methotrexate and the c
APA, Harvard, Vancouver, ISO, and other styles
20

Simpson, Eric, Lawrence Eichenfield, James Del Rosso, et al. "Roflumilast Cream 0.15% in Patients with Atopic Dermatitis: Individual Patient Response from the Pooled INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials." SKIN The Journal of Cutaneous Medicine 8, no. 2 (2024): s372. http://dx.doi.org/10.25251/skin.8.supp.372.

Full text
Abstract:
Introduction: Roflumilast cream 0.15% is a highly selective phosphodiesterase 4 inhibitor under investigation as a once-daily, nonsteroidal treatment for atopic dermatitis (AD). Pooled safety and efficacy results of two Phase 3 clinical trials (INTEGUMENT-1 and INTEGUMENT-2) in patients with AD have been presented previously. Here we present individual patient responses on the Eczema Area and Severity Index (EASI), which is used to assess disease severity in clinical trials. Methods: INTEGUMENT-1 and INTEGUMENT-2 were identical, randomized, double-blind, vehicle-controlled, 4-week trials of on
APA, Harvard, Vancouver, ISO, and other styles
21

Tyrrell, Jean, Xiaozhong Qian, Jose Freire, and Robert Tarran. "Roflumilast combined with adenosine increases mucosal hydration in human airway epithelial cultures after cigarette smoke exposure." American Journal of Physiology-Lung Cellular and Molecular Physiology 308, no. 10 (2015): L1068—L1077. http://dx.doi.org/10.1152/ajplung.00395.2014.

Full text
Abstract:
Chronic obstructive pulmonary disease (COPD) is a growing cause of morbidity and mortality worldwide. Recent studies have shown that cigarette smoke (CS) induces cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction, which leads to airway-surface liquid (ASL) dehydration. This in turn contributes to the mucus dehydration and impaired mucociliary clearance that are seen in the chronic bronchitis form of COPD. Roflumilast is a phosphodiesterase 4 inhibitor that may improve lung function and reduce the frequency of exacerbations in patients with COPD. Although roflumilast can aff
APA, Harvard, Vancouver, ISO, and other styles
22

Kazmi, Imran, Fahad A. Al-Abbasi, Muhammad Afzal, Muhammad Shahid Nadeem, Hisham N. Altayb, and Gaurav Gupta. "Phosphodiesterase-4 Inhibitor Roflumilast-Mediated Protective Effect in Sepsis-Induced Late-Phase Event of Acute Kidney Injury: A Narrative Review." Pharmaceuticals 15, no. 7 (2022): 899. http://dx.doi.org/10.3390/ph15070899.

Full text
Abstract:
Severe infections such as viral, bacterial, or fungal sepsis can cause an inflammatory response in the host, leading to organ failure and septic shock—phosphodiesterase-4 (PDE-4) inhibiting related agents from suppressing cyclic adenosine monophosphate (cAMP) degradation. Regulatory organisations have approved some substances in this category to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with chronic bronchitis and a history of COPD exacerbations. Roflumilast has been shown to alleviate inflammatory responses, thus regulating airway inflammation.
APA, Harvard, Vancouver, ISO, and other styles
23

Gooderham, Melinda, Jerry Bagel, Seth Forman, et al. "Patient-Reported Outcomes with Roflumilast Foam 0.3% in Patients with Psoriasis of the Scalp and Body in the Phase 3 ARRECTOR Trial." SKIN The Journal of Cutaneous Medicine 9, no. 2 (2025): s525. https://doi.org/10.25251/skin.10.supp.525.

Full text
Abstract:
Introduction: Patients with psoriasis of the scalp or body consider itch the most burdensome symptom. Roflumilast is a highly potent phosphodiesterase 4 inhibitor under investigation as a novel, once-daily foam for treatment of psoriasis of the scalp and body. The impact of roflumilast foam 0.3% on patient-reported outcomes (PROs) in patients with psoriasis of the scalp and body from the phase 3 trial (ARRECTOR; NCT05028582) are reported here. Methods: Patients aged ≥12 years with psoriasis of the scalp and body affecting ≤25% of overall body surface area, minimum Scalp-Investigator Global Ass
APA, Harvard, Vancouver, ISO, and other styles
24

Del Rosso, James, H. Chih-ho Hong, Leon Kircik, et al. "Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Individual Patient Response from the Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials." SKIN The Journal of Cutaneous Medicine 8, no. 1 (2024): s310. http://dx.doi.org/10.25251/skin.8.supp.310.

Full text
Abstract:
Roflumilast cream 0.3% in patients with chronic plaque psoriasis: individual patient response from the pooled DERMIS-1 and DERMIS-2 phase 3 trials
 
 James Del Rosso1 on behalf of the authors
 
 INTRODUCTION: Roflumilast cream 0.3% is a highly potent phosphodiesterase 4 inhibitor approved as a nonsteroidal, once-daily treatment for patients with plaque psoriasis. The efficacy and safety of the pooled results of two Phase 3 clinical trials (DERMIS-1 and DERMIS-2) in patients aged ≥2 years with plaque psoriasis have been previously presented. We present individual patient res
APA, Harvard, Vancouver, ISO, and other styles
25

Lebwohl, Mark G., Leon H. Kircik, Angela Y. Moore, et al. "Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis." JAMA 328, no. 11 (2022): 1073. http://dx.doi.org/10.1001/jama.2022.15632.

Full text
Abstract:
ImportanceOnce-daily roflumilast cream, 0.3%, a potent phosphodiesterase 4 inhibitor, demonstrated efficacy and was well tolerated in a phase 2b trial of patients with psoriasis.ObjectiveTo evaluate the efficacy of roflumilast cream, 0.3%, applied once daily for 8 weeks in 2 trials of patients with plaque psoriasis.Design, Setting, and ParticipantsTwo phase 3, randomized, double-blind, controlled, multicenter trials (DERMIS-1 [trial 1; n = 439] and DERMIS-2 [trial 2; n = 442]) were conducted at 40 centers (trial 1) and 39 centers (trial 2) in the US and Canada between December 9, 2019, and Nov
APA, Harvard, Vancouver, ISO, and other styles
26

Zeng, Shasha, Haibing Bai та Mi Zou. "Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting β2 Agonist: A Meta-analysis". Computational and Mathematical Methods in Medicine 2022 (23 липня 2022): 1–9. http://dx.doi.org/10.1155/2022/8101099.

Full text
Abstract:
Objective. Roflumilast is a novel therapeutic drug for chronic obstructive pulmonary disease (COPD). This study was designed to evaluate the efficacy and safety of roflumilast combining inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) in treating COPD patients through the meta-analysis. Methods. Randomized controlled trials of roflumilast combining ICS/LABA in treating patients with severe and profound COPD were searched from PubMed, Cochrane Library, and Embase databases from their establishment to February 2022. The quality of included studies was assessed by Cochrane risk bias ass
APA, Harvard, Vancouver, ISO, and other styles
27

Hassan, Ghida, Sherif A. Kamar, Hagar Yousry Rady, Dina Sayed Abdelrahim, Nesma Hussein Abdel Hay Ibrahim, and Noha N. Lasheen. "A study of roflumilast treatment on functional and structural changes in hippocampus in depressed Adult male Wistar rats." PLOS ONE 19, no. 2 (2024): e0296187. http://dx.doi.org/10.1371/journal.pone.0296187.

Full text
Abstract:
Depression is a common stress disability disorder that affects higher mental functions including emotion, cognition, and behavior. It may be mediated by inflammatory cytokines that interfere with neuroendocrine function, and synaptic plasticity. Therefore, reductions in inflammation might contribute to treatment response. The current study aims to evaluate the role of Protein Kinase (PKA)- cAMP response element-binding protein (CREB)- brain derived neurotropic factor (BDNF) signaling pathway in depression and the effects of roflumilast (PDE4 inhibitor) as potential antidepressant on the activi
APA, Harvard, Vancouver, ISO, and other styles
28

Botrugno, Rachel, Bijaya Rajlawat, Daniel Finn, and Paul Devakar Yesudian. "P099 Use of roflumilast in erosive oral inflammatory conditions." British Journal of Dermatology 191, Supplement_1 (2024): i62—i63. http://dx.doi.org/10.1093/bjd/ljae090.126.

Full text
Abstract:
Abstract Roflumilast is a phosphodiesterase type 4 (PDE4) inhibitor commonly used in respiratory medicine to manage chronic obstructive lung disease. Recently, there have been case reports of its effectiveness in oral mucosal conditions. We review five patients with different erosive mucosal lesions who responded to this medication. All patients were commenced on 250 μg daily, increasing to 500 μg if indicated. Case 1 is a 57-year-old woman who presented to the dermatology/oral medicine (DOM) clinic with long-standing recurrent aphthous stomatitis from her late teens. Treatment with colchicine
APA, Harvard, Vancouver, ISO, and other styles
29

Syfridiana, Rafina, and Fauna Herawati. "Roflumilast: Review of Phosphodiesterase-4 Inhibitor as Asthma Therapy." Journal of Health Sciences 14, no. 3 (2021): 214–21. http://dx.doi.org/10.33086/jhs.v14i3.2114.

Full text
Abstract:
Asthma is a heterogeneous disease characterized by chronic inflammation of the airways induced reversible obstruction resulting in mortality and morbidity. Roflumilast is a second-generation selective inhibitor of phosphodiesterase-4 targeting PDE type 4 isoenzymes, disturbing the breakdown of cyclic AMP (cAMP) and reducing inflammation. However, it has not been recommended for asthma patients because of insufficient evidence from trial results. The search was carried out using the PUBMED online database from 2011 to May 2021. The keywords used in this study were "Asthma" and "Roflumilast" usi
APA, Harvard, Vancouver, ISO, and other styles
30

Prasad, N. Nukendra, R. Venkata Nadh, and N. Srinivasu. "Validated HPLC Method for Assay and Content Uniformity Testing of Roflumilast in Blend and Tablets." Asian Journal of Chemistry 32, no. 6 (2020): 1279–85. http://dx.doi.org/10.14233/ajchem.2020.22373.

Full text
Abstract:
Roflumilast is a selective enzyme inhibitor of phosphodiesterase-4. This drug is recommended for treatment of patients suffering from chronic-obstructive-pulmonary-disease with chronic-bronchitis. Roflumilast is not official in pharmacopoeia and the reported methods are having high chromatographic run times. A short run time HPLC method was developed for assay and content uniformity testing to determine the roflumilast in blend and tablets. The mobile phase consists of 10 mM sodium dihydrogen phosphate monohydrate buffer and acetonitrile in the ratio of 45:55 v/v. The HPLC method was developed
APA, Harvard, Vancouver, ISO, and other styles
31

Izquierdo, J. L., and J. Aparicio. "Roflumilast for COPD." Drugs of Today 46, no. 11 (2010): 823. http://dx.doi.org/10.1358/dot.2010.46.11.1521831.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Worndl, Erin, Eoin B. Hunt, Marcus P. Kennedy, Michael T. Henry, Barry J. Plant, and Desmond M. Murphy. "Roflumilast in COPD." Chest 148, no. 1 (2015): e31. http://dx.doi.org/10.1378/chest.15-0664.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Chu, David, Brett Stephenson, Jeff Lee, et al. "Clinical Efficacy and Patient Reported Impacts of Roflumilast Foam 0.3% in Seborrheic Dermatitis: An Analysis of STRATUM Data for Patients Unresponsive or Intolerant to Topical Corticosteroids." SKIN The Journal of Cutaneous Medicine 8, no. 2 (2024): s397. http://dx.doi.org/10.25251/skin.8.supp.397.

Full text
Abstract:
Objective. Roflumilast foam 0.3% has demonstrated efficacy and tolerability in a Phase 3 clinical trial of moderate-to-severe seborrheic dermatitis (SD) patients (STRATUM). The aim of this subgroup analysis is to assess the efficacy and patient-reported quality of life (QOL) effects of roflumilast vs vehicle in patients with an inadequate response, intolerance, or contraindication to topical corticosteroids (TCS).
 Methods: Patients 9 years or older with at least moderate seborrheic dermatitis (Investigator Global Assessment [IGA] ≥ 3) were randomized 2:1 to roflumilast or vehicle for 8 w
APA, Harvard, Vancouver, ISO, and other styles
34

Guitard, Nathalie, Florent Raffin, and François-Xavier Boittin. "The Phosphodiesterase 4 Inhibitor Roflumilast Protects Microvascular Endothelial Cells from Irradiation-Induced Dysfunctions." Cells 14, no. 13 (2025): 1017. https://doi.org/10.3390/cells14131017.

Full text
Abstract:
In endothelial cells, high-dose irradiation induces numerous dysfunctions including alteration in junctional proteins such as VE-Cadherin, apoptosis and enhanced adhesiveness linked to overexpression of adhesion molecules like Intercellular Adhesion Molecule 1 (ICAM-1). Such endothelial dysfunctions can lead to altered tissue perfusion, development of tissue inflammation through increased endothelial permeability, and ultimately organ damage. As intracellular cyclic AMP (cAMP) levels are known to control intercellular junctions or apoptosis in the endothelium, we investigated here the effect o
APA, Harvard, Vancouver, ISO, and other styles
35

Lee, Byung-Cheol, Seiko Susuki-Miyata, Chen Yan, and Jian-Dong Li. "Dexamethasone Inhibits Synergistic Induction of PDE4B Expression by Roflumilast and Bacterium NTHi." International Journal of Molecular Sciences 19, no. 11 (2018): 3511. http://dx.doi.org/10.3390/ijms19113511.

Full text
Abstract:
Phosphodiesterase 4B (PDE4B) plays an important role in inflammation. Recently we have reported that roflumilast as a PDE4-selective inhibitor, synergizes with nontypeable Haemophilus influenzae (NTHi) to up-regulate PDE4B expression in vitro and in vivo. Clinical evidence and our previous results suggest that synergistic induction of PDE4B could be counterproductive for suppressing inflammation or may contribute to tolerance to roflumilast. We thus investigated if dexamethasone inhibits the synergistic induction of PDE4B by roflumilast and NTHi as well as inflammation. Here, dexamethasone mar
APA, Harvard, Vancouver, ISO, and other styles
36

DOMINGUES, ERIK. "Recalcitrant Scalp Psoriasis Successfully Treated with Once-Daily Roflumilast Cream 0.3%." SKIN The Journal of Cutaneous Medicine 8, no. 6 (2024): s417. http://dx.doi.org/10.25251/skin.8.supp.417.

Full text
Abstract:
Scalp psoriasis is a chronic, immune-mediated skin disease with varying phenotypes and is estimated to affect up to 80% of individuals suffering from psoriasis [1]. The physical symptoms, along with social and emotional impacts of scalp psoriasis can significantly reduce quality of life, necessitating long-term treatment for most patients [3]. Numerous topical and systemic treatments are available for scalp psoriasis, yet the condition remains challenging to manage, underscoring a persistent unmet need for safe and effective therapies [2]. Treatment of the scalp and other hair bearing areas is
APA, Harvard, Vancouver, ISO, and other styles
37

Blauvelt, Andrew, Javier Alonso-Llamazares, Neal Bhatia, et al. "Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial." SKIN The Journal of Cutaneous Medicine 7, no. 2 (2023): s196. http://dx.doi.org/10.25251/skin.7.supp.196.

Full text
Abstract:
Introduction: Seborrheic dermatitis (SD) is a common, chronic, inflammatory dermatosis that affects patients of all ages with a global prevalence ≥5%. Treatments usually consist of topical therapies, including antifungals and low potency corticosteroids; however, current treatments have limitations such as side effects with long-term use and/or vehicles that can be difficult to use on both hair-bearing and non-hair-bearing areas. Roflumilast is a selective, nonsteroidal, highly potent phosphodiesterase-4 inhibitor once-daily foam under investigation for the treatment of SD. Efficacy, safety, a
APA, Harvard, Vancouver, ISO, and other styles
38

Matencio, Adrián, Samanta Hernández-García, Francisco García-Carmona, and José Manuel López-Nicolás. "A Way to Increase the Bioaccesibility and Photostability of Roflumilast, a COPD Treatment, by Cyclodextrin Monomers." Polymers 11, no. 5 (2019): 801. http://dx.doi.org/10.3390/polym11050801.

Full text
Abstract:
Roflumilast is an orally available inhibitor of phosphodiesterase (PDE) type 4, which is widely used in chronic obstructive pulmonary diseases. However, it has low solubility and adverse effects include diarrhea and nausea. Since its solubilization may improve treatment and, dismissing any adverse effects, its interaction with cyclodextrins (CDs) was studied. The Higuchi-Connors method was used to determine the complexation constant with different CDs, pH values and temperatures. Molecular docking was used to predict interaction between the complexes. An in vitro digestion experiment was carri
APA, Harvard, Vancouver, ISO, and other styles
39

Field, Stephen K. "Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations." Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 5 (January 2011): CCRPM.S7049. http://dx.doi.org/10.4137/ccrpm.s7049.

Full text
Abstract:
Acute exacerbations of COPD (AECOPD) are major clinical events. They are associated with a more rapid decline in lung function, poorer quality of life scores, and an increased risk of dying. Exacerbations that require hospitalization have particular significance. Approximately 40% of the AECOPD patients who require hospitalization will die in the subsequent year. Since many AECOPD require hospitalization, they account for most of the expense of caring for COPD patients. Treatment with long-acting bronchodilators and combination inhaled corticosteroid/long-acting bronchodilator inhalers reduces
APA, Harvard, Vancouver, ISO, and other styles
40

Bunick, Christopher, Neal Bhatia, James Del Rosso, et al. "Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis." SKIN The Journal of Cutaneous Medicine 8, no. 1 (2024): s309. http://dx.doi.org/10.25251/skin.8.supp.309.

Full text
Abstract:
Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
 
 Christopher G. Bunick1 on behalf of the authors
 
 INTRODUCTION: Formulating a topical medication that does not irritate the skin is an important factor contributing to patient treatment adherence and satisfaction. Many topical prescription products use penetration enhancers (including propylene glycol, polyethylene glycol, and ethanol) to overcome barrier properties of the skin. However, these excipients may
APA, Harvard, Vancouver, ISO, and other styles
41

Suzuki, Osamu, Taiji Goto, Toshiharu Yoshino, Satoshi Nakamura, and Hiroaki Maeda. "The role of phosphodiesterase 4B in IL-8/LTB4-induced human neutrophil chemotaxis evaluated with a phosphodiesterase 4B inhibitor." Acta Pharmaceutica 65, no. 2 (2015): 191–97. http://dx.doi.org/10.1515/acph-2015-0016.

Full text
Abstract:
Abstract PDE4B was previously shown to be a dominant PDE4 subtype of neutrophils. However, its physiological role in the neutrophil function has not been evaluated. In this study, the inhibitory effects of a phosphodiesterase 4B (PDE4B)- selective inhibitor (compound A) and subtype non-selective PDE4 inhibitors (roflumilast and cilomilast) were evaluated in human peripheral blood cells. Compound A, roflumilast and cilomilast in a similar manner inhibited TNF-α production by LPS-stimulated human mononuclear cells. However, the inhibitory effect of compound A on IL-8 or LTB4-induced chemotactic
APA, Harvard, Vancouver, ISO, and other styles
42

Si, Yu Hui, Gang Chun Sun, Ge Song, Wen Peng Mai, and Zhi Cheng Li. "Synthesis and Characterization of Novel Roflumilast Analogues." Advanced Materials Research 781-784 (September 2013): 1190–93. http://dx.doi.org/10.4028/www.scientific.net/amr.781-784.1190.

Full text
Abstract:
A series of new roflumilast analogues with Crown ether structures were designed and synthesized. Crown-ether-type benzaldehydes were first prepared from 3,4-dihydroxybenzaldehyde with 1-bromo-3-chloropropane and 1-chloro-2-(2-chloroethoxy) ethane respectively, then after oxidation, acylation and amidation as the last step with 3,5-dichloropyridin-4-amine the roflumilast analogues were obtained. These compounds were characterised by1H NMR, IR, ESI-MS and elemental analysis.
APA, Harvard, Vancouver, ISO, and other styles
43

Duque, Adolfo E. Diaz, Pedro S. S. M. Ferrari, Purushoth Ethiraj, et al. "First-Line Combination of R-CHOP with the PDE4 Inhibitor Roflumilast for High-Risk DLBCL." Cancers 16, no. 22 (2024): 3857. http://dx.doi.org/10.3390/cancers16223857.

Full text
Abstract:
Background: Diffuse large B-cell lymphoma (DLBCL) is a common and often fatal malignancy. The standard-of-care immunochemotherapy, R-CHOP, cures only about 60% of DLBCL patients. Improving this cure rate will likely require the effective translation of basic biology knowledge into clinical activities. We previously identified the cyclic-AMP/phosphodiesterase 4 (PDE4) axis as an important modulator of lymphomagenic processes. We also showed that the FDA-approved PDE4 inhibitor roflumilast can suppress B-cell receptor (BCR) signals, phosphoinositide 3-kinase (PI3K) activity and angiogenesis. The
APA, Harvard, Vancouver, ISO, and other styles
44

Lim, Je-Oh, Woong-Il Kim, Se-Jin Lee, et al. "The Involvement of PDE4 in the Protective Effects of Melatonin on Cigarette-Smoke-Induced Chronic Obstructive Pulmonary Disease." Molecules 26, no. 21 (2021): 6588. http://dx.doi.org/10.3390/molecules26216588.

Full text
Abstract:
Chronic obstructive pulmonary disease (COPD) is a significant disease threatening human health. Currently, roflumilast, a phosphodiesterase (PDE)4 inhibitor, is recommended as a therapeutic agent for COPD. In this study, we investigated the therapeutic effects of melatonin against COPD, focusing on determining whether it is a PDE4 inhibitor via in vivo and in vitro experiment using cigarette smoke (CS) and cigarette smoke condensate (CSC), respectively. In the in vivo experiments, melatonin treatment reduced inflammatory responses, including inflammatory cell counts. Melatonin treatment also s
APA, Harvard, Vancouver, ISO, and other styles
45

Arkhipov, V. V. "Clinical pharmacology of roflumilast." Russian Pulmonology, no. 2 (January 1, 2012): 90–98. http://dx.doi.org/10.18093/0869-0189-2012-0-2-90-98.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Rho, Jason, Nancy Ho, and Vinay Prasad. "Roflumilast in COPD: Response." Chest 148, no. 1 (2015): e31-e32. http://dx.doi.org/10.1378/chest.15-0837.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Cortijo Gimeno, Julio, and Esteban Morcillo Sánchez. "Perfil farmacológico del roflumilast." Archivos de Bronconeumología 46 (January 2010): 19–24. http://dx.doi.org/10.1016/s0300-2896(10)70052-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Izquierdo Alonso, José Luis. "Perfil clínico del roflumilast." Archivos de Bronconeumología 46 (January 2010): 25–32. http://dx.doi.org/10.1016/s0300-2896(10)70053-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Gupta, Steve. "Side-effects of roflumilast." Lancet 379, no. 9817 (2012): 710–11. http://dx.doi.org/10.1016/s0140-6736(12)60304-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Carraro, Chiara Francesca. "Two cases of COPD benefitting from therapy with roflumilast." Monaldi Archives for Chest Disease 79, no. 3-4 (2015). http://dx.doi.org/10.4081/monaldi.2013.29.

Full text
Abstract:
Two clinical cases of chronic obstructive pulmonary disease (COPD) stage II patients are reported here. One case refers to a patient with hypoxemia associated to severe air flow limitation, chronic bronchitis and frequent exacerbation events. A significant improvement of patient’s conditions was observed after pharmacological treatment with roflumilast. The second case refers to a patient who refused to adhere to prescribed therapy but adhered to roflumilast therapy, eventually achieving a good response. Both cases highlight roflumilast’s efficacy in improving health conditions of COPD patient
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!